Ir a la página de inicio del Gobierno del Principado de Asturias

Datos del Documento

Utilice este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/8729


Título: X-linked hypophosphatemia and growth
Autores: Fuente, Rocío
Gil Peña, Helena
Claramunt Taberner, Débora
Hernádez, Olaya
Fernández Iglesias, Ángela
Alonso Durán, Laura
Rodríguez Rubio, Enrique
Santos, Fernando
Fecha Edición: 27-Ene-2017
Cita Bibliográfica: R. Fuente, H. Gil-Peña, D. Claramunt-Taberner, O. Hernández,A. Fernández-Iglesias,L. Alonso-Durán, E. Rodríguez-Rubio and F. Santos. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017 Mar;18(1):107-115.
Resumen: X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating levels of fibroblast growth factor 23 (FGF23). Short stature and rachitic osseous lesions are characteristic phenotypic findings of XLH although the severity of these manifestations is highly variable among patients. The degree of growth impairment is not dependent on the magnitude of hypophosphatemia or the extent of legs´ bowing and height is not normalized by chronic administration of phosphate supplements and 1α hydroxyvitamin D derivatives. Treatment with growth hormone accelerates longitudinal growth rate but there is still controversy regarding the potential risk of increasing bone deformities and body disproportion. Treatments aimed at blocking FGF23 action are promising, but information is lacking on the consequences of counteracting FGF23 during the growing period. This review summarizes current knowledge on phosphorus metabolism in XLH, presents updated information on XLH and growth, including the effects of FGF23 on epiphyseal growth plate of the Hyp mouse, an animal model of the disease, and discusses growth hormone and novel FGF23 related therapies.
Descripción : PDF formato impresión
URI: https://ria.asturias.es/RIA/handle/123456789/8729
Aparece en las Colecciones:Bioquímica

Archivos en este documento:



Archivo TamañoFormato
Archivo.pdf730,17 kBAdobe PDFVer/Abrir



logo

Todos los documentos en RIA están protegidos por derechos de autor.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Contacto